ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $389,375 | -87.0% | 34,859 | -75.1% | 0.00% | – |
| Q2 2023 | $3,001,521 | -69.1% | 140,258 | -41.6% | 0.00% | – |
| Q1 2023 | $9,713,768 | -21.1% | 240,202 | -9.3% | 0.00% | -100.0% |
| Q4 2022 | $12,315,844 | -23.6% | 264,743 | -14.8% | 0.00% | -50.0% |
| Q3 2022 | $16,116,000 | -2.7% | 310,695 | -11.3% | 0.00% | 0.0% |
| Q2 2022 | $16,560,000 | -3.9% | 350,333 | +44.7% | 0.00% | +100.0% |
| Q1 2022 | $17,238,000 | +1723700.0% | 242,172 | +2018000.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 12 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 12 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -66.7% | 12 | -77.8% | 0.00% | – |
| Q2 2020 | $3,000 | -99.5% | 54 | -99.6% | 0.00% | – |
| Q1 2020 | $627,000 | -74.8% | 12,195 | -69.7% | 0.00% | – |
| Q4 2019 | $2,489,000 | -48.1% | 40,295 | -49.5% | 0.00% | -100.0% |
| Q3 2019 | $4,794,000 | -63.0% | 79,795 | -48.0% | 0.00% | -50.0% |
| Q2 2019 | $12,943,000 | -43.6% | 153,395 | -36.1% | 0.00% | -33.3% |
| Q1 2019 | $22,944,000 | +61.2% | 240,195 | +19.5% | 0.00% | +50.0% |
| Q4 2018 | $14,236,000 | -42.4% | 200,995 | -30.5% | 0.00% | -33.3% |
| Q3 2018 | $24,699,000 | -37.9% | 289,020 | -15.8% | 0.00% | -40.0% |
| Q2 2018 | $39,764,000 | +43.2% | 343,092 | 0.0% | 0.01% | +66.7% |
| Q1 2018 | $27,760,000 | +62.4% | 343,092 | +17.8% | 0.00% | +50.0% |
| Q4 2017 | $17,094,000 | +29.6% | 291,315 | +3.4% | 0.00% | 0.0% |
| Q3 2017 | $13,189,000 | +32.4% | 281,815 | +1.8% | 0.00% | +100.0% |
| Q2 2017 | $9,960,000 | +12.7% | 276,815 | -3.5% | 0.00% | 0.0% |
| Q1 2017 | $8,834,000 | -32.7% | 286,815 | -26.8% | 0.00% | -50.0% |
| Q4 2016 | $13,126,000 | +19.8% | 391,815 | -4.9% | 0.00% | +100.0% |
| Q3 2016 | $10,958,000 | -29.1% | 411,815 | -41.2% | 0.00% | -50.0% |
| Q2 2016 | $15,449,000 | -19.0% | 700,653 | +7.9% | 0.00% | -33.3% |
| Q1 2016 | $19,065,000 | -21.9% | 649,115 | -12.1% | 0.00% | 0.0% |
| Q4 2015 | $24,396,000 | -29.2% | 738,815 | -22.5% | 0.00% | -40.0% |
| Q3 2015 | $34,441,000 | -19.7% | 952,988 | 0.0% | 0.01% | 0.0% |
| Q2 2015 | $42,875,000 | +3.0% | 952,988 | -29.9% | 0.01% | 0.0% |
| Q1 2015 | $41,626,000 | -61.7% | 1,359,435 | -36.3% | 0.01% | -64.3% |
| Q4 2014 | $108,578,000 | +36.6% | 2,135,258 | +6.3% | 0.01% | +27.3% |
| Q3 2014 | $79,477,000 | -7.9% | 2,008,508 | +0.3% | 0.01% | -8.3% |
| Q2 2014 | $86,278,000 | -12.6% | 2,003,208 | -18.8% | 0.01% | -14.3% |
| Q1 2014 | $98,684,000 | +178.6% | 2,467,708 | +90.0% | 0.01% | +180.0% |
| Q4 2013 | $35,423,000 | – | 1,298,476 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |